AST-1306 TsOH

Allitinib tosylate (AST-1306 TsOH) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.IC50 value: 0.5/3 nM (EGFR/Erb2)[1]Target: EGFR/Erb2;Mutant EGFR T790M/L858RAllitinib functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2

Alitinib (AST-1306) is a structural analog of lapatinib, a new quinazoline anti-tumor drug, and a small molecule epidermal growth factor receptor tyrosine kinase inhibitor, which selectively acts on EGFR/ErbB2 /ErbB4 receptor.

Molecular Weight:621.1
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:9
Rotatable Bond Count:8
Exact Mass:620.1296470
Monoisotopic Mass:620.1296470
Topological Polar Surface Area:139
Heavy Atom Count:43
Complexity:848
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes